3-[(2-dimethylaminoethyl)-methyl-amino]-phenol | 945733-17-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-[(2-dimethylaminoethyl)-methyl-amino]-phenol
• 英文别名: 3-[2-(Dimethylamino)ethyl-methylamino]phenol
• CAS: 945733-17-5
• 化学式: C₁₁H₁₈N₂O
• 分子量: 194.277
• InChiKey: AGWCCJRPMDRAGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TRIAZOLE DERIVATIVE
  申请人：Ono Naoya

  公开号：US20100041655A1

  公开（公告）日：2010-02-18

  An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P 1 ), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below (where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO 2 — or the like, R 1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R 1A represents a hydrogen atom or the like, R 2 represents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, represents an aryl group, R 4 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and R 5 represents an alkyl group having 1-carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).

  本发明的目的是提供一种化合物，具有抑制S1P与其受体Edg-1（S1P1）结合的作用，并且可用作制药化合物。该化合物或其药学上可接受的盐，所述化合物由以下公式表示（其中A表示氧原子、硫原子、由公式—SO—表示的基团、由公式—SO2—表示的基团或类似基团，R1表示氢原子、具有1-6个碳原子的烷基或类似基团，R1A表示氢原子或类似基团，R2表示具有1-6个碳原子的烷基、具有3-6个碳原子的环烷基或类似基团，表示芳基基团，R4表示氢原子或具有1-6个碳原子且可选择性地取代羧基的烷基基团，而R5表示具有1个碳原子的烷基基团、具有3-8个碳原子的环烷基、可选择性地取代的芳基基团或类似基团）。
• ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20160194304A1

  公开（公告）日：2016-07-07

  Compounds of formula (I): wherein Het, R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , T, p, p′, q, and q′ are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物：其中，Het、R3、R4、R5、R7、R8、R9、T、p、p'、q和q'的定义如说明书所述。包含这些化合物的药物制剂在治疗涉及凋亡缺陷的病理学方面有用，例如癌症、自身免疫性疾病和免疫系统疾病。
• Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：LES LABORATOIRES SERVIER

  公开号：US10689364B2

  公开（公告）日：2020-06-23

  Compounds of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, T, p, p′, q, and q′ are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

  式(I)化合物： 其中 Het、R3、R4、R5、R7、R8、R9、T、p、p′、q 和 q′ 如说明中所定义。 含有相同成分的医药产品，可用于治疗需要促凋亡剂的病症。
• NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Les Laboratoires Servier

  公开号：EP3024826B1

  公开（公告）日：2018-11-14
• US8022091B2
  申请人：——

  公开号：US8022091B2

  公开（公告）日：2011-09-20